Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cleveland, Ohio 44106


Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.


Inclusion Criteria: - Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24 - Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study - Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder - Patient must be at least 18 years old - Patient must be willing to give a blood sample Exclusion Criteria: - Patient lacks the capacity to provide informed consent



Primary Contact:

Principal Investigator
Jinbo Fan, PhD
Case Western Reserve University

Backup Contact:


Location Contact:

Cleveland, Ohio 44106
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.